Lunai Bioworks(纳斯达克代码:Lnai)已与Brainstorm Therapeutics达成最终合作协议,这一合作明确聚焦于帕金森病领域。双方共同将首个关键数据读出节点设定在2027年上半年。这项协议标志着两家公司在神经退行性疾病治疗方面迈出了实质性的一步,旨在通过资源整合加速研发进程。
Lunai Bioworks(纳斯达克代码:Lnai)已与Brainstorm Therapeutics达成最终合作协议,这一合作明确聚焦于帕金森病领域。双方共同将首个关键数据读出节点设定在2027年上半年。这项协议标志着两家公司在神经退行性疾病治疗方面迈出了实质性的一步,旨在通过资源整合加速研发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.